JP2015506981A5 - - Google Patents

Download PDF

Info

Publication number
JP2015506981A5
JP2015506981A5 JP2014556712A JP2014556712A JP2015506981A5 JP 2015506981 A5 JP2015506981 A5 JP 2015506981A5 JP 2014556712 A JP2014556712 A JP 2014556712A JP 2014556712 A JP2014556712 A JP 2014556712A JP 2015506981 A5 JP2015506981 A5 JP 2015506981A5
Authority
JP
Japan
Prior art keywords
composition
glucose
methyl
subject
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014556712A
Other languages
English (en)
Japanese (ja)
Other versions
JP6084238B2 (ja
JP2015506981A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/025294 external-priority patent/WO2013119917A1/en
Publication of JP2015506981A publication Critical patent/JP2015506981A/ja
Publication of JP2015506981A5 publication Critical patent/JP2015506981A5/ja
Application granted granted Critical
Publication of JP6084238B2 publication Critical patent/JP6084238B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014556712A 2012-02-08 2013-02-08 下痢を処置するための材料および方法 Active JP6084238B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261596480P 2012-02-08 2012-02-08
US61/596,480 2012-02-08
PCT/US2013/025294 WO2013119917A1 (en) 2012-02-08 2013-02-08 Materials and methods for treating diarrhea

Publications (3)

Publication Number Publication Date
JP2015506981A JP2015506981A (ja) 2015-03-05
JP2015506981A5 true JP2015506981A5 (enExample) 2015-04-30
JP6084238B2 JP6084238B2 (ja) 2017-02-22

Family

ID=48948047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014556712A Active JP6084238B2 (ja) 2012-02-08 2013-02-08 下痢を処置するための材料および方法

Country Status (15)

Country Link
US (4) US20140377374A1 (enExample)
EP (1) EP2812007B1 (enExample)
JP (1) JP6084238B2 (enExample)
KR (2) KR102262179B1 (enExample)
CN (1) CN104093410B (enExample)
AP (1) AP3941A (enExample)
AU (1) AU2013216871B2 (enExample)
BR (1) BR112014019350B1 (enExample)
CA (1) CA2863388C (enExample)
EA (1) EA034014B1 (enExample)
ES (1) ES2862392T3 (enExample)
HK (1) HK1204290A1 (enExample)
IN (1) IN2014DN06737A (enExample)
MX (1) MX368543B (enExample)
WO (1) WO2013119917A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030970B8 (ru) 2010-09-24 2019-01-31 Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. Композиция для восстановления функции тонкого кишечника, способы ее приготовления и применения
EP4417256A3 (en) 2013-03-11 2024-10-23 University of Florida Research Foundation, Inc. Materials and methods for improving lung function
CN107106527B (zh) 2014-11-24 2020-11-24 恩特林斯科健康解决方案股份公司 用于治疗疾病症状的氨基酸组合物
CA3135553C (en) 2016-10-04 2024-05-21 University Of Florida Research Foundation, Incorporated Amino acid compositions and uses thereof
WO2019070753A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA
WO2020251906A1 (en) * 2019-06-12 2020-12-17 The Regents Of The University Of California Methods of treating bile acid diarrhea
CN115916185B (zh) * 2020-06-02 2025-09-26 佛罗里达大学研究基金会公司 用于治疗腹泻的制剂和方法
IL299488A (en) * 2020-07-02 2023-02-01 Univ Florida Preparations for promoting hydration and methods of using them
AU2022280087A1 (en) * 2021-05-28 2023-12-14 The Coca-Cola Company Amino acid hydration formulation and method of use
CN115531363B (zh) * 2021-06-30 2024-03-29 中国科学技术大学 预防、抑制或治疗轮状病毒感染的药物组合物及其用途
US11878073B1 (en) * 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290538A (en) * 1988-12-22 1994-03-01 Skrezek Christian Nephro protective infusion solutions
JP3301646B2 (ja) * 1993-03-19 2002-07-15 シスメックス株式会社 幼若細胞測定用試薬
KR19980703876A (ko) * 1995-04-14 1998-12-05 스티븐 엘. 허스트 분산성이 개선된 분말화된 약학적 조성물
JP4255656B2 (ja) * 2001-09-17 2009-04-15 株式会社メニコン 眼科用液剤及びコンタクトレンズ用液剤
US20030143293A1 (en) * 2002-01-31 2003-07-31 Sergei Shushunov Compositions and methods for treating diarrhea
JP2004123642A (ja) * 2002-10-04 2004-04-22 Shimizu Pharmaceutical Co Ltd 電解質組成物
DK175877B1 (da) * 2002-11-11 2005-05-09 Pharmalett As Præparater til anvendelse som terapeutisk middel
US20050100637A1 (en) * 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
JP4811576B2 (ja) * 2005-03-31 2011-11-09 味の素株式会社 水分電解質補給飲料
JP4512013B2 (ja) * 2005-09-07 2010-07-28 和光堂株式会社 液体飲料組成物及びその製造方法
DE102006018293A1 (de) * 2006-04-20 2007-10-25 Fresenius Kabi Deutschland Gmbh Pädiatrische Aminosäurelösung zur parenteralen Ernäherung
EA030970B8 (ru) * 2010-09-24 2019-01-31 Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. Композиция для восстановления функции тонкого кишечника, способы ее приготовления и применения
EP4417256A3 (en) * 2013-03-11 2024-10-23 University of Florida Research Foundation, Inc. Materials and methods for improving lung function

Similar Documents

Publication Publication Date Title
RU2016119746A (ru) Стабильный состав инсулина глулизин
EP4233892A3 (en) Stable anti-ifnar1 formulation
JP2018138578A5 (enExample)
JP2021502980A5 (enExample)
NZ608502A (en) Polypeptides that bind to human complement component c5
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
JP2022119854A5 (enExample)
JP2015510888A5 (enExample)
HRP20210945T1 (hr) Formulacije protutijela anti-cd19
JP2016539921A5 (enExample)
JP2016520050A5 (enExample)
RU2600440C3 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
HRP20241526T1 (hr) Stabilni višedozni pripravci, koji sadrže protutijelo i konzervans
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
JP2011502997A5 (enExample)
RU2015139742A (ru) Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
CA3019769C (en) Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
HRP20220011T1 (hr) Nova stabilna formulacija za fxia protutijela
HK1204290A1 (en) Materials and methods for treating diarrhea
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
BR112022002392A2 (pt) Formas em estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1)-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e seus usos